DAIICHI SANKYO COMPANY, LIMITED Logo

DAIICHI SANKYO COMPANY, LIMITED

A global pharmaceutical firm developing novel therapies with a focus on oncology and ADCs.

4568 | T

Overview

Corporate Details

ISIN(s):
JP3475350009
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目5番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Daiichi Sankyo is a global pharmaceutical company focused on the research, development, and delivery of innovative medical solutions. The company's core business revolves around creating novel therapies, with a primary strategic focus on oncology. It is a leader in the science of antibody-drug conjugates (ADCs), a class of targeted cancer drugs. Beyond oncology, its portfolio and development pipeline include treatments for cardiovascular diseases and other specialty areas. The company manufactures and markets a range of prescription medicines, vaccines, and over-the-counter healthcare products, aiming to contribute to the enrichment of quality of life for patients worldwide by creating new standards of care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 05:22
Registration Form
確認書
Japanese 8.2 KB
2025-11-07 05:19
Interim Report
半期報告書-第21期(2025/04/01-2026/03/31)
Japanese 321.7 KB
2025-10-10 02:55
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-10-03 04:15
Registration Form
発行登録追補書類(株券、社債券等)
Japanese 130.8 KB
2025-09-05 03:06
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.3 KB
2025-08-07 05:49
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.8 KB
2025-07-17 02:04
Registration Form
発行登録書(株券、社債券等)
Japanese 24.8 KB
2025-07-09 02:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-06-24 06:02
Registration Form
訂正発行登録書
Japanese 8.9 KB
2025-06-24 05:36
Post-Annual General Meeting Information
臨時報告書
Japanese 25.7 KB
2025-06-23 08:40
Registration Form
訂正発行登録書
Japanese 8.9 KB
2025-06-23 07:44
Share Issue/Capital Change
臨時報告書
Japanese 31.3 KB
2025-06-20 07:20
Governance Information
内部統制報告書-第20期(2024/04/01-2025/03/31)
Japanese 23.5 KB
2025-06-20 07:20
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 07:19
Annual Report
有価証券報告書-第20期(2024/04/01-2025/03/31)
Japanese 3.0 MB

Automate Your Workflow. Get a real-time feed of all DAIICHI SANKYO COMPANY, LIMITED filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DAIICHI SANKYO COMPANY, LIMITED

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DAIICHI SANKYO COMPANY, LIMITED via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ANAVEX LIFE SCIENCES CORP. Logo
Developing precision therapeutics for neurodegenerative and CNS disorders.
United States of America
AVXL
Anbio Biotechnology Logo
Develops and supplies in vitro diagnostic solutions for human and veterinary markets.
United States of America
NNNN
Anebulo Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing an antidote for acute cannabinoid intoxication in ER patients.
United States of America
ANEB
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan
4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom
ANCR
ANI PHARMACEUTICALS INC Logo
Develops, manufactures, and markets branded/generic drugs and OTCs for niche therapeutic areas.
United States of America
ANIP
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden
ANNX
Annexon, Inc. Logo
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea
065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania
ATB

Talk to a Data Expert

Have a question? We'll get back to you promptly.